Product Description
Domain nominated DT-9045 as a first-in-class PAR2 NAM clinical candidate based on its added-value, unique properties and greater therapeutic potential in comparison to biologics targeting PAR2 currently in the clinic by several competitors. DT-9045 has demonstrated proof-of-concept efficacy in syngeneic models potentiating the anti-tumor activity of an anti-PD1 treatment. (Sourced from: https://www.domaintherapeutics.com/domain-therapeutics-announces-nomination-of-first-in-class-par2-nam-candidate-dt-9045-to-unlock-new-cancer-treatment-possibilities/)
Mechanisms of Action: PAR2 Modulator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Domain Therapeutics
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
04/08/2024 |
News Article |
Domain Therapeutics to Participate at Premier Investor and Healthcare Conferences |
|
03/26/2024 |
News Article |
Domain Therapeutics to Present Latest Data on DT-9045, a First-in-class Negative Allosteric Modulator of PAR2 for Immuno-oncology, at AACR 2024 Annual Meeting, Highlighting Clear Competitive Advantages of This Candidate |
|
02/27/2024 |
News Article |
Domain Therapeutics Promotes Stephan Schann as Chief Scientific Officer (CSO) |
|
07/28/2023 |
News Article |
Latest Updates of 7 Viva's Portfolio Companies |